Study of A-319 for B-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug (A-319) that targets CD19, a protein on leukemia cells, to help your immune system attack the cancer. It is for people with B-cell acute lymphoblastic leukemia that has relapsed, is resistant to treatment, or still has minimal disease after chemo (MRD-positive). The study aims to see if this drug can help you reach remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 75 years.
- Diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) that has either come back after treatment, is no longer responding, or still has leftover cancer cells in the bone marrow after chemotherapy.
- You must have a protein called CD19 on your leukemia cells.
- You must be well enough to carry out daily activities (ECOG score 0-2).
- If you've had a stem cell transplant, there must be no problems with graft-versus-host disease.
- You must not have leukemia affecting the brain or spinal cord, or have had certain other cancers in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This trial tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL). The treatment takes your own immune cells, changes them to fight cancer, and then gives them back to you. The goal is to kill leukemia cells and help you go into remission.
This trial is testing a new cell therapy called SNC116 for adults with a type of leukemia (B-cell acute lymphoblastic leukemia) that has come back or not responded to standard treatments. The therapy targets a protein called CD19 on the cancer cells to try to destroy them.
This trial tests an experimental cell therapy using your own immune cells (gamma-delta T cells) that are engineered to find and kill cancer cells that carry a protein called CD19. It is for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
Hear when a new Acute Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.